Pyrotinib Boosts Survival in HER2+ Metastatic Breast Cancer Pyrotinib Boosts Survival in HER2+ Metastatic Breast Cancer

Patients treated with pyrotinib plus capecitabine survived longer than those treated with lapatinib plus capecitabine in the PHOEBE trial.Medscape Medical News
Source: Medscape Hematology-Oncology Headlines - Category: Cancer & Oncology Tags: Hematology-Oncology News Source Type: news